QIAGEN Gains 510(k) Clearance by FDA for QIAstat-Dx in the U.S. and Launches System as Next Generation Platform for Syndromic Insights

Molecular diagnostic testing for accurate clinical insights on hard-to-diagnose syndromes, initial launch with respiratory panel for detection of more than 20 pathogens QIAGEN N.V. (NYSE:QGEN; Fra...